took the survey during December 29, 2020–January 21, 2021. During this time, there were no active Ebola virus outbreaks in the world. Summary What is already known about this topic? Preexposure vaccination against Ebola virus disease is currently recommended for adults aged ≥18 years in the United States who are at highest risk for occupational exposure to Ebola virus. What is added by this report? The Advisory Committee on Immunization Practices has expanded recommendations to include two additional populations at high risk for potential occupational exposure to Ebola virus: health care personnel at special pathogens treatment centers and laboratorians and support staff members at Laboratory Response Network facilities. What are the implications for public health practice? Ebola virus remains an international and domestic public health threat. Preexposure vaccination can protect those at occupational risk for exposure to Ebola virus. choice to get vaccinated at different time points (i.e., when an EVD case is imported to the United States, or when an EVD case is imported to their state), willingness to receive vaccine increased to 86%. When asked whether they believed that ACIP should recommend the vaccine for their population, 59% responded yes, 9% responded no, and 33% were unsure. Rationale Similar to the initial groups for whom the vaccine was recommended in February 2020, the decision to recommend preexposure vaccination in these groups was based on the following conditions: 1) documented protective efficacy of the vaccine against the development of symptomatic EVD, 2) high mortality and severity of illness in persons infected with Ebola virus, 3) high transmissibility of Ebola virus, 4) EVD-related sequelae in survivors, 5) the potential for continued disease transmission and disease recrudescence, and 6) an acceptable safety profile relative to the severity of Ebola virus infection. Recommendations Preexposure vaccination with ERVEBO is now also recommended for adults aged ≥18 years in the U.S. population who are at high risk for potential occupational exposure to Ebola virus: • Health care personnel involved in the care and transport of patients with suspected or confirmed EVD at SPTCs, or • Laboratorians and support staff members at LRN facilities that handle specimens that might contain replicationcompetent Ebola virus (species Zaire ebolavirus) in the United States. Morbidity and Mortality Weekly Report 292 MMWR / February 25, 2022 / Vol. 71 / No. 8 US Department of Health and Human Services/Centers for Disease Control and Prevention Future Research and Monitoring Priorities Research regarding ERVEBO is ongoing, including safety of ERVEBO in immunocompromised persons, pregnant women, and children. The same considerations and recommendations for these special populations apply as in the initial recommendations (1). In addition, long-term studies are continuing to assess immunogenicity and duration of protection. ACIP will consider these data as they become available and revise recommendations accordingly. Acknowledgments Members of the Advisory Committee on Immunization Practices; member roster as of November 2021 is available (https://www.cdc. gov/vaccines/acip/members/index.html). Corresponding author: Jason H. Malenfant, rix3@cdc.gov. 1Epidemic Intelligence Service, CDC; 2Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3Baylor College of Medicine, Houston, Texas; 4University of Washington, Seattle, Washington; 5Idaho Department of Health and Welfare; 6Cayuga Family Medicine, Ithaca, New York; 7National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; 8Médicins Sans Frontières, Brussels, Belgium; 9Emory University, Atlanta, Georgia; 10Saint Louis University School of Medicine, St. Louis, Missouri; 11University of Maryland School of Medicine, Baltimore, Maryland. All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed. References 1. Choi MJ, Cossaboom CM, Whitesell AN, et al. Use of Ebola vaccine: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2021;70:1–12. PMID:33417593 https://doi.org/10.15585/mmwr.rr7001a1 2. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849–62. PMID:21084112 https://doi.org/10.1016/ S0140-6736(10)60667-8 3. Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007;196(Suppl 2):S142–7. PMID:17940942 https://doi. org/10.1086/520545 4. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 1999;179(Suppl 1):S87–91. PMID:9988169 https://doi.org/10.1086/514284 5. Sissoko D, Keïta M, Diallo B, et al. Ebola virus persistence in breast milk after no reported illness: a likely source of virus transmission from mother to child. Clin Infect Dis